Bankrupt PhaseBio Pharma Finds Buyers for Secondary Assets After Auction -- Market Talk
1601 ET - Publicly traded PhaseBio Pharmaceuticals, which has already reached a deal to sell its key drug program during its bankruptcy, says it has also found proposed buyers for its secondary assets
SFJ Pharmaceuticals Announces Closing of Transfer of Bentracimab Assets From PhaseBio Pharmaceuticals
SFJ Pharmaceuticals ("SFJ" or the "company") today announced the closing of the sale and transfer of assets related to Bentracimab from PhaseBio Pharmaceuticals, Inc. ("PhaseBio") to SFJ. The sale and transfer was
Delisting of Securities of PhaseBio Pharmaceuticals, Inc.; Zovio Inc.; Fast Radius, Inc.; and Kismet Acquisition Three Corp. From The Nasdaq Stock Market
NEW YORK, Dec. 20, 2022 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock of PhaseBio Pharmaceuticals, Inc. PhaseBio Pharmaceuticals, Inc.'s common stock was suspended on
PhaseBio Pharmaceuticals (NASDAQ:PHAS) Trading Up 7%
PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS – Get Rating) shares were up 7% during trading on Wednesday . The stock traded as high as $0.11 and last traded at $0.10. Approximately 455,938 shares chan
Bankrupt PhaseBio Identifies Chiesi as Lead Bidder for Bentracimab Assets
By Becky Yerak Chiesi Farmaceutici SpA has been named as the lead bidder for the key assets of PhaseBio Pharmaceuticals Inc., a publicly traded drug developer that is in chapter 11 bankruptcy. Phase
Head-To-Head Contrast: Alpine Immune Sciences (NASDAQ:ALPN) Vs. PhaseBio Pharmaceuticals (NASDAQ:PHAS)
Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) and PhaseBio Pharmaceuticals (NASDAQ:PHAS – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the
Head to Head Analysis: PhaseBio Pharmaceuticals (NASDAQ:PHAS) Vs. Alpine Immune Sciences (NASDAQ:ALPN)
PhaseBio Pharmaceuticals (NASDAQ:PHAS – Get Rating) and Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the
Wall Street Set to Open Higher Ahead of Manufacturing PMI, Fed Meeting
09:10 AM EDT, 11/01/2022 (MT Newswires) -- U.S. stocks look set to open Tuesday higher as investors look to extend October's winning streak into November, and ahead of the manufacturing PMI reading la
Top Premarket Gainers
07:29 AM EDT, 11/01/2022 (MT Newswires) -- Abiomed (ABMD) shares surged nearly 52% premarket Tuesday after it agreed to be acquired by Johnson & Johnson (JNJ) for $380 in cash per share, represent
Why Goodyear Tire & Rubber Shares Are Trading Lower; Here Are 24 Stocks Moving Premarket
Gainers Quotient Limited (NASDAQ:QTNT) rose 60.7% to $0.1295 in pre-market trading. Quotient shares dipped 37% on Monday after the company announced a 1-for-40 reverse stock split.PhaseBio Pharmaceuti
Enterprise Associates 13 L. New Sells 1,784,109 Shares of PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) Stock
PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS – Get Rating) major shareholder Enterprise Associates 13 L. New sold 1,784,109 shares of the firm's stock in a transaction dated Tuesday, October 25th. The
Cowen Downgrades PhaseBio Pharmaceuticals to Market Perform From Outperform
05:20 AM EDT, 10/25/2022 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co
PhaseBio Pharmaceuticals (NASDAQ:PHAS) Downgraded to "Market Perform" at Cowen
Cowen lowered shares of PhaseBio Pharmaceuticals (NASDAQ:PHAS – Get Rating) from an outperform rating to a market perform rating in a report published on Monday morning, The Fly reports. Several othe
News Highlights: Top Company News of the Day
Cerebral to Cut About 20% of Workers as It Shrinks Operations
PhaseBio Pharmaceuticals Files for Chapter 11, Plans to Sell Assets; Shares Plunge
10:39 AM EDT, 10/24/2022 (MT Newswires) -- PhaseBio Pharmaceuticals (PHAS) said Monday it has filed for Chapter 11 bankruptcy with a Delaware court and plans to file a motion seeking authorization to
PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) Sees Large Decline in Short Interest
PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS – Get Rating) was the target of a large decrease in short interest during the month of September. As of September 15th, there was short interest totalling
PhaseBio Pharmaceuticals (NASDAQ:PHAS) Stock Rating Lowered by Stifel Nicolaus
PhaseBio Pharmaceuticals (NASDAQ:PHAS – Get Rating) was downgraded by stock analysts at Stifel Nicolaus from a "buy" rating to a "hold" rating in a report released on Wednesday, The Fly reports. They
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Immunovant (NASDAQ:IMVT) shares increased by 29.2% to $6.19 during Thursday's regular session. Immunovant's stock is trading at a volume of 3.3 million shares as of 13:30 EST. This is 991.6% o
PhaseBio Shares Are Trading Lower After the Company on Wednesday Announced It Received a Notice That Its Partner SFJ Pharmaceuticals Group Elected to Transfer Bentracimab Rights to SFJ as PhaseBio Failed to Remedy Its Going Concern Condition.
PhaseBio shares are trading lower after the company on Wednesday announced it received a notice that its partner SFJ Pharmaceuticals Group elected to transfer bentracimab rights to SFJ as PhaseBio fai
PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) Short Interest Down 18.3% in September
PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS – Get Rating) was the recipient of a significant decline in short interest during the month of September. As of September 15th, there was short interest to
No Data